Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of ...

Continuing the upmanship battle in expanding the use of GLP-1 drugs beyond diabetes and obesity, Novo Nordisk has released ...

The REACH study included data from 58,336 Medicare patients aged 66 years and older with T2D and ASCVD who had initiated either semaglutide or dulaglutide.

The wildly popular Ozempic drug cuts heart attack, stroke and death risk by nearly 25% in older patients, according to a new ...

The two observational studies have limitations, including use of older GLP-1s, but still point to the strengths of bariatric ...

Ozempic® (once-weekly injectable semaglutide) was associated with a 23% reduced risk of heart attack, stroke and death in ...

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg ...

A new drug has shown significant promise as an effective diabetes and weight loss treatment—and can be produced more cheaply.

Discover comprehensive details about Dulaglutide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio SAN FRANCISCO — A 1.5 mg daily dose of ...

Compared with a combination of insulin glargine, metformin and glimepiride, once-weekly dulaglutide demonstrated superiority and noninferiority as a type 2 diabetes therapy with two different doses, ...

Eli Lilly needs a big win to offset recent high profile patent expirations and that's why the company's recent release of data for its promising GLP-1 diabetes drug dulaglutide is so important. If ...